Loading…

Renal and Auditory Toxicity of High-Dose, Prolonged Therapy with Gentamicin and Tobramycin in Pseudomonas Endocarditis

The nephrotoxicity and auditory toxicity of high-dose (mean, 28.6 g) and prolonged (mean, 61.6 days) courses of gentamicin and tobramycin were monitored in 15 patients receiving 17 courses of treatment for pseudomonas endocarditis. Doses were adjusted in a manner that maintained peak levels of amino...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1984-02, Vol.149 (2), p.257-263
Main Authors: Tablan, Ofelia C., Reyes, Milagros P., Rintelmann, William F., Lerner, A. Martin
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c414t-9e9accfb0e0c49b89eaf60223a9a724e4719d4d0e4cbd7ba4fa52f3bc14a80f33
cites
container_end_page 263
container_issue 2
container_start_page 257
container_title The Journal of infectious diseases
container_volume 149
creator Tablan, Ofelia C.
Reyes, Milagros P.
Rintelmann, William F.
Lerner, A. Martin
description The nephrotoxicity and auditory toxicity of high-dose (mean, 28.6 g) and prolonged (mean, 61.6 days) courses of gentamicin and tobramycin were monitored in 15 patients receiving 17 courses of treatment for pseudomonas endocarditis. Doses were adjusted in a manner that maintained peak levels of aminoglycoside in serum at 12–15 µg/ml and trough levels at < 2 µg/ml. Drug-related renal dysfunction and auditory toxicity occurred in 63% and 44%, respectively, of gentamicin-treated patients and in 43% and 25%, respectively, of tobramycin-treated patients. Mean maximal rises (± SEM).in serum creatinine levels were 0.8 (± 0.4) mg/dl in the group given gentamicin and 1.6 (± 0.7) mg/dl in the group given tobramycin. Mean maximal decreases in pure-tone hearing threshold levels were greater in gentamicin-treated patients (58.3 dB) than in those given tobramycin (22.5 dB). Both forms of toxicity appeared earlier and at a smaller dose with gentamicin than with tobramycin.
doi_str_mv 10.1093/infdis/149.2.257
format article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_13834826</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30109716</jstor_id><sourcerecordid>30109716</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-9e9accfb0e0c49b89eaf60223a9a724e4719d4d0e4cbd7ba4fa52f3bc14a80f33</originalsourceid><addsrcrecordid>eNpFkM1v0zAYhy0EGmVw54KUA-JEOjt24_g4jbGCJphQEIiL9cYfq0did3YCy3-PS0uRLFnW7-N9_SD0kuAlwYKeOW-1S2eEiWW1rFb8EVqQFeVlXRP6GC0wrqqSNEI8Rc9SusMYM1rzE3RSs4oIxhbo1xfjoS_A6-J80m4McS7a8OCUG-ci2GLtbjflu5DM2-Imhj74W6OLdmMibOfitxs3xZXxIww54P-2tKGLMMy7Zz43yUw6DMFDKi69DgpiHuLSc_TEQp_Mi8N9ir6-v2wv1uX156sPF-fXpWKEjaUwApSyHTZYMdE1woCt858oCOAVM4wToZnGhqlO8w6YhVVlaacIgwZbSk_Rm33vNob7yaRRDi4p0_fgTZiSJLShrKnqbMR7o4ohpWis3EY3QJwlwXKHWu5Ry4xaVjKjzpFXh-6pG4w-Bg5ss_76oENS0NsIXuWCfzZR10Jw8r_mLmX6R5niPJWT3WblXndpNA9HHeJPWXPKV3L9_Yds2bc1EfST_Ej_AGV_oxk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>13834826</pqid></control><display><type>article</type><title>Renal and Auditory Toxicity of High-Dose, Prolonged Therapy with Gentamicin and Tobramycin in Pseudomonas Endocarditis</title><source>Oxford University Press Archive</source><source>JSTOR</source><creator>Tablan, Ofelia C. ; Reyes, Milagros P. ; Rintelmann, William F. ; Lerner, A. Martin</creator><creatorcontrib>Tablan, Ofelia C. ; Reyes, Milagros P. ; Rintelmann, William F. ; Lerner, A. Martin</creatorcontrib><description>The nephrotoxicity and auditory toxicity of high-dose (mean, 28.6 g) and prolonged (mean, 61.6 days) courses of gentamicin and tobramycin were monitored in 15 patients receiving 17 courses of treatment for pseudomonas endocarditis. Doses were adjusted in a manner that maintained peak levels of aminoglycoside in serum at 12–15 µg/ml and trough levels at &lt; 2 µg/ml. Drug-related renal dysfunction and auditory toxicity occurred in 63% and 44%, respectively, of gentamicin-treated patients and in 43% and 25%, respectively, of tobramycin-treated patients. Mean maximal rises (± SEM).in serum creatinine levels were 0.8 (± 0.4) mg/dl in the group given gentamicin and 1.6 (± 0.7) mg/dl in the group given tobramycin. Mean maximal decreases in pure-tone hearing threshold levels were greater in gentamicin-treated patients (58.3 dB) than in those given tobramycin (22.5 dB). Both forms of toxicity appeared earlier and at a smaller dose with gentamicin than with tobramycin.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/149.2.257</identifier><identifier>PMID: 6421944</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Administered dose ; Adult ; Aminoglycosides ; Antibiotics ; Auditory perception ; Auditory Threshold ; Biological and medical sciences ; Creatinine - blood ; Dosage ; Drug toxicity and drugs side effects treatment ; Endocarditis ; Endocarditis, Bacterial - drug therapy ; Female ; Gentamicins - administration &amp; dosage ; Gentamicins - adverse effects ; Hearing loss ; Hearing Loss - chemically induced ; Hearing Loss, Bilateral - chemically induced ; Humans ; Infections ; Kidney Diseases - blood ; Kidney Diseases - chemically induced ; Male ; Medical sciences ; Nephrotoxicity ; Pharmacology. Drug treatments ; Pseudomonas ; Pseudomonas aeruginosa ; Pseudomonas Infections - drug therapy ; Tobramycin - administration &amp; dosage ; Tobramycin - adverse effects ; Toxicity: urogenital system</subject><ispartof>The Journal of infectious diseases, 1984-02, Vol.149 (2), p.257-263</ispartof><rights>Copyright 1984 The University of Chicago</rights><rights>1984 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-9e9accfb0e0c49b89eaf60223a9a724e4719d4d0e4cbd7ba4fa52f3bc14a80f33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30109716$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30109716$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,58219,58452</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=9669971$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6421944$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tablan, Ofelia C.</creatorcontrib><creatorcontrib>Reyes, Milagros P.</creatorcontrib><creatorcontrib>Rintelmann, William F.</creatorcontrib><creatorcontrib>Lerner, A. Martin</creatorcontrib><title>Renal and Auditory Toxicity of High-Dose, Prolonged Therapy with Gentamicin and Tobramycin in Pseudomonas Endocarditis</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>The nephrotoxicity and auditory toxicity of high-dose (mean, 28.6 g) and prolonged (mean, 61.6 days) courses of gentamicin and tobramycin were monitored in 15 patients receiving 17 courses of treatment for pseudomonas endocarditis. Doses were adjusted in a manner that maintained peak levels of aminoglycoside in serum at 12–15 µg/ml and trough levels at &lt; 2 µg/ml. Drug-related renal dysfunction and auditory toxicity occurred in 63% and 44%, respectively, of gentamicin-treated patients and in 43% and 25%, respectively, of tobramycin-treated patients. Mean maximal rises (± SEM).in serum creatinine levels were 0.8 (± 0.4) mg/dl in the group given gentamicin and 1.6 (± 0.7) mg/dl in the group given tobramycin. Mean maximal decreases in pure-tone hearing threshold levels were greater in gentamicin-treated patients (58.3 dB) than in those given tobramycin (22.5 dB). Both forms of toxicity appeared earlier and at a smaller dose with gentamicin than with tobramycin.</description><subject>Administered dose</subject><subject>Adult</subject><subject>Aminoglycosides</subject><subject>Antibiotics</subject><subject>Auditory perception</subject><subject>Auditory Threshold</subject><subject>Biological and medical sciences</subject><subject>Creatinine - blood</subject><subject>Dosage</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Endocarditis</subject><subject>Endocarditis, Bacterial - drug therapy</subject><subject>Female</subject><subject>Gentamicins - administration &amp; dosage</subject><subject>Gentamicins - adverse effects</subject><subject>Hearing loss</subject><subject>Hearing Loss - chemically induced</subject><subject>Hearing Loss, Bilateral - chemically induced</subject><subject>Humans</subject><subject>Infections</subject><subject>Kidney Diseases - blood</subject><subject>Kidney Diseases - chemically induced</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nephrotoxicity</subject><subject>Pharmacology. Drug treatments</subject><subject>Pseudomonas</subject><subject>Pseudomonas aeruginosa</subject><subject>Pseudomonas Infections - drug therapy</subject><subject>Tobramycin - administration &amp; dosage</subject><subject>Tobramycin - adverse effects</subject><subject>Toxicity: urogenital system</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1984</creationdate><recordtype>article</recordtype><recordid>eNpFkM1v0zAYhy0EGmVw54KUA-JEOjt24_g4jbGCJphQEIiL9cYfq0did3YCy3-PS0uRLFnW7-N9_SD0kuAlwYKeOW-1S2eEiWW1rFb8EVqQFeVlXRP6GC0wrqqSNEI8Rc9SusMYM1rzE3RSs4oIxhbo1xfjoS_A6-J80m4McS7a8OCUG-ci2GLtbjflu5DM2-Imhj74W6OLdmMibOfitxs3xZXxIww54P-2tKGLMMy7Zz43yUw6DMFDKi69DgpiHuLSc_TEQp_Mi8N9ir6-v2wv1uX156sPF-fXpWKEjaUwApSyHTZYMdE1woCt858oCOAVM4wToZnGhqlO8w6YhVVlaacIgwZbSk_Rm33vNob7yaRRDi4p0_fgTZiSJLShrKnqbMR7o4ohpWis3EY3QJwlwXKHWu5Ry4xaVjKjzpFXh-6pG4w-Bg5ss_76oENS0NsIXuWCfzZR10Jw8r_mLmX6R5niPJWT3WblXndpNA9HHeJPWXPKV3L9_Yds2bc1EfST_Ej_AGV_oxk</recordid><startdate>198402</startdate><enddate>198402</enddate><creator>Tablan, Ofelia C.</creator><creator>Reyes, Milagros P.</creator><creator>Rintelmann, William F.</creator><creator>Lerner, A. Martin</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>198402</creationdate><title>Renal and Auditory Toxicity of High-Dose, Prolonged Therapy with Gentamicin and Tobramycin in Pseudomonas Endocarditis</title><author>Tablan, Ofelia C. ; Reyes, Milagros P. ; Rintelmann, William F. ; Lerner, A. Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-9e9accfb0e0c49b89eaf60223a9a724e4719d4d0e4cbd7ba4fa52f3bc14a80f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1984</creationdate><topic>Administered dose</topic><topic>Adult</topic><topic>Aminoglycosides</topic><topic>Antibiotics</topic><topic>Auditory perception</topic><topic>Auditory Threshold</topic><topic>Biological and medical sciences</topic><topic>Creatinine - blood</topic><topic>Dosage</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Endocarditis</topic><topic>Endocarditis, Bacterial - drug therapy</topic><topic>Female</topic><topic>Gentamicins - administration &amp; dosage</topic><topic>Gentamicins - adverse effects</topic><topic>Hearing loss</topic><topic>Hearing Loss - chemically induced</topic><topic>Hearing Loss, Bilateral - chemically induced</topic><topic>Humans</topic><topic>Infections</topic><topic>Kidney Diseases - blood</topic><topic>Kidney Diseases - chemically induced</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nephrotoxicity</topic><topic>Pharmacology. Drug treatments</topic><topic>Pseudomonas</topic><topic>Pseudomonas aeruginosa</topic><topic>Pseudomonas Infections - drug therapy</topic><topic>Tobramycin - administration &amp; dosage</topic><topic>Tobramycin - adverse effects</topic><topic>Toxicity: urogenital system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tablan, Ofelia C.</creatorcontrib><creatorcontrib>Reyes, Milagros P.</creatorcontrib><creatorcontrib>Rintelmann, William F.</creatorcontrib><creatorcontrib>Lerner, A. Martin</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tablan, Ofelia C.</au><au>Reyes, Milagros P.</au><au>Rintelmann, William F.</au><au>Lerner, A. Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Renal and Auditory Toxicity of High-Dose, Prolonged Therapy with Gentamicin and Tobramycin in Pseudomonas Endocarditis</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>1984-02</date><risdate>1984</risdate><volume>149</volume><issue>2</issue><spage>257</spage><epage>263</epage><pages>257-263</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>The nephrotoxicity and auditory toxicity of high-dose (mean, 28.6 g) and prolonged (mean, 61.6 days) courses of gentamicin and tobramycin were monitored in 15 patients receiving 17 courses of treatment for pseudomonas endocarditis. Doses were adjusted in a manner that maintained peak levels of aminoglycoside in serum at 12–15 µg/ml and trough levels at &lt; 2 µg/ml. Drug-related renal dysfunction and auditory toxicity occurred in 63% and 44%, respectively, of gentamicin-treated patients and in 43% and 25%, respectively, of tobramycin-treated patients. Mean maximal rises (± SEM).in serum creatinine levels were 0.8 (± 0.4) mg/dl in the group given gentamicin and 1.6 (± 0.7) mg/dl in the group given tobramycin. Mean maximal decreases in pure-tone hearing threshold levels were greater in gentamicin-treated patients (58.3 dB) than in those given tobramycin (22.5 dB). Both forms of toxicity appeared earlier and at a smaller dose with gentamicin than with tobramycin.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>6421944</pmid><doi>10.1093/infdis/149.2.257</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-1899
ispartof The Journal of infectious diseases, 1984-02, Vol.149 (2), p.257-263
issn 0022-1899
1537-6613
language eng
recordid cdi_proquest_miscellaneous_13834826
source Oxford University Press Archive; JSTOR
subjects Administered dose
Adult
Aminoglycosides
Antibiotics
Auditory perception
Auditory Threshold
Biological and medical sciences
Creatinine - blood
Dosage
Drug toxicity and drugs side effects treatment
Endocarditis
Endocarditis, Bacterial - drug therapy
Female
Gentamicins - administration & dosage
Gentamicins - adverse effects
Hearing loss
Hearing Loss - chemically induced
Hearing Loss, Bilateral - chemically induced
Humans
Infections
Kidney Diseases - blood
Kidney Diseases - chemically induced
Male
Medical sciences
Nephrotoxicity
Pharmacology. Drug treatments
Pseudomonas
Pseudomonas aeruginosa
Pseudomonas Infections - drug therapy
Tobramycin - administration & dosage
Tobramycin - adverse effects
Toxicity: urogenital system
title Renal and Auditory Toxicity of High-Dose, Prolonged Therapy with Gentamicin and Tobramycin in Pseudomonas Endocarditis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T13%3A13%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Renal%20and%20Auditory%20Toxicity%20of%20High-Dose,%20Prolonged%20Therapy%20with%20Gentamicin%20and%20Tobramycin%20in%20Pseudomonas%20Endocarditis&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Tablan,%20Ofelia%20C.&rft.date=1984-02&rft.volume=149&rft.issue=2&rft.spage=257&rft.epage=263&rft.pages=257-263&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1093/infdis/149.2.257&rft_dat=%3Cjstor_proqu%3E30109716%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c414t-9e9accfb0e0c49b89eaf60223a9a724e4719d4d0e4cbd7ba4fa52f3bc14a80f33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=13834826&rft_id=info:pmid/6421944&rft_jstor_id=30109716&rfr_iscdi=true